Literature DB >> 26905679

Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis.

Ana Lucia Andrade1, Ruth Minamisava2, Gabriela Policena1, Elier B Cristo3, Carla Magda S Domingues4, Maria Cristina de Cunto Brandileone5, Samanta Cristine Grassi Almeida5, Cristiana Maria Toscano1, Ana Luiza Bierrenbach1.   

Abstract

Routine infant immunization with 10-valent pneumococcal conjugate vaccine (PCV-10) began in Brazil in 2010. The impact of the PCV-10 on rates of invasive pneumococcal disease (IPD) at the population level was not yet evaluated. Serotype-specific IPD changes after PCV-10 introduction is still to be determined. Data from national surveillance system for notifiable diseases (SINAN) and national reference laboratory for S. pneumoniae in Brazil (IAL) were linked to enhance case ascertainment of IPD. An interrupted time-series analysis was conducted to predict trends in the postvaccination IPD rates in the absence of PCV-10 vaccination, taking into consideration seasonality and secular trends. PCVs serotype-specific distribution were assessed before (2008-2009) and after (2011-2013) the introduction of PCV-10 in the immunization program. A total of 9,827 IPD cases were identified from 2008-2013 when combining SINAN and IAL databases. Overall, PCV-10 types decreased by 41.3% after PCV-10 vaccination period, mostly in children aged 2-23 months, while additional PCV-13 serotypes increased by 62.8% mainly in children under 5-year of age. For children aged 2-23 months, targeted by the immunization program, we observed a 44.2% (95%CI, 15.8-72.5%) reduction in IPD rates. In contrast, significant increase in IPD rates were observed for adults aged 18-39 y (18.9%, 95%CI 1.1-36.7%), 40-64 y (52.5%, 95%CI 24.8-80.3%), and elderly ≥ 65 y (79.3%, 95%CI 62.1-96.5%). This is the first report of a time-series analysis for PCV impact in IPD conducted at national level data in a developing country. We were able to show significant impact of PCV-10 on IPD for age groups targeted by vaccination in Brazil, 3 y after its introduction. No impact on other age groups was demonstrated.

Entities:  

Keywords:  Streptococcus pneumoniae; data linkage; impact; interrupted time-series analysis; invasive pneumococcal disease; meningitis; pneumococcal vaccines; surveillance

Mesh:

Substances:

Year:  2016        PMID: 26905679      PMCID: PMC5049745          DOI: 10.1080/21645515.2015.1117713

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  20 in total

1.  [Epidemiologic surveillance and evaluation of meningitis hospital care].

Authors:  Claudia Caminha Escosteguy; Roberto de Andrade Medronho; Roberto Madruga; Hellen Gruezo Dias; Ricardo Cerqueira Braga; Otília Pimenta Azevedo
Journal:  Rev Saude Publica       Date:  2004-10-18       Impact factor: 2.106

2.  Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Pneumococcal Disease.

Authors:  Arto A Palmu; Terhi M Kilpi; Hanna Rinta-Kokko; Hanna Nohynek; Maija Toropainen; J Pekka Nuorti; Jukka Jokinen
Journal:  Pediatrics       Date:  2015-06-15       Impact factor: 7.124

3.  Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Authors:  Matthew R Moore; Ruth Link-Gelles; William Schaffner; Ruth Lynfield; Catherine Lexau; Nancy M Bennett; Susan Petit; Shelley M Zansky; Lee H Harrison; Arthur Reingold; Lisa Miller; Karen Scherzinger; Ann Thomas; Monica M Farley; Elizabeth R Zell; Thomas H Taylor; Tracy Pondo; Loren Rodgers; Lesley McGee; Bernard Beall; James H Jorgensen; Cynthia G Whitney
Journal:  Lancet Infect Dis       Date:  2015-02-03       Impact factor: 25.071

4.  Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era: South Africa, 2003-2008.

Authors:  Anne von Gottberg; Cheryl Cohen; Linda de Gouveia; Susan Meiring; Vanessa Quan; Andrew Whitelaw; Penny Crowther-Gibson; Shabir A Madhi; Cynthia G Whitney; Keith P Klugman
Journal:  Vaccine       Date:  2013-05-16       Impact factor: 3.641

5.  Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.

Authors:  Zitta Barrella Harboe; Tine Dalby; Daniel M Weinberger; Thomas Benfield; Kåre Mølbak; Hans Christian Slotved; Camilla H Suppli; Helle Bossen Konradsen; Palle Valentiner-Branth
Journal:  Clin Infect Dis       Date:  2014-07-16       Impact factor: 9.079

6.  Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

7.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

8.  Bacterial Meningitis in Brazil: Baseline Epidemiologic Assessment of the Decade Prior to the Introduction of Pneumococcal and Meningococcal Vaccines.

Authors:  Luciano Cesar Pontes Azevedo; Cristiana M Toscano; Ana Luiza Bierrenbach
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

9.  Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study.

Authors:  Carla Magda Allan S Domingues; Jennifer R Verani; Ernesto Issac Montenegro Renoiner; Maria Cristina de Cunto Brandileone; Brendan Flannery; Lucia Helena de Oliveira; João Barberino Santos; José Cássio de Moraes
Journal:  Lancet Respir Med       Date:  2014-04-10       Impact factor: 30.700

10.  Validation of a hierarchical deterministic record-linkage algorithm using data from 2 different cohorts of human immunodeficiency virus-infected persons and mortality databases in Brazil.

Authors:  Antonio G Pacheco; Valeria Saraceni; Suely H Tuboi; Lawrence H Moulton; Richard E Chaisson; Solange C Cavalcante; Betina Durovni; José C Faulhaber; Jonathan E Golub; Bonnie King; Mauro Schechter; Lee H Harrison
Journal:  Am J Epidemiol       Date:  2008-10-09       Impact factor: 4.897

View more
  15 in total

1.  Reply to Varghese et al.'s response to Wu et al. - "Cost effectiveness analysis of infant pneumococcal vaccination in Malaysia and Hong Kong".

Authors:  David Bin-Chia Wu; Kenneth Kwing Chin Lee; Vivian Wing Yan Lee; Li-Wen Hong
Journal:  Hum Vaccin Immunother       Date:  2016-10-02       Impact factor: 3.452

2.  Impact and effectiveness of a conjugate vaccine against invasive pneumococcal disease in Finland - a modelling approach.

Authors:  Hanna Rinta-Kokko; Markku Nurhonen; Kari Auranen
Journal:  Hum Vaccin Immunother       Date:  2020-12-17       Impact factor: 3.452

3.  Reduction in all-cause otitis media-related outpatient visits in children after PCV10 introduction in Brazil.

Authors:  Ana L Sartori; Ruth Minamisava; Ana L Bierrenbach; Cristiana M Toscano; Eliane T Afonso; Otaliba L Morais-Neto; José L F Antunes; Elier B Cristo; Ana Lucia Andrade
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

Review 4.  From Immunologically Archaic to Neoteric Glycovaccines.

Authors:  Marco Cavallari; Gennaro De Libero
Journal:  Vaccines (Basel)       Date:  2017-01-27

5.  Combined effect of PCV10 and meningococcal C conjugate vaccination on meningitis mortality among children under five years of age in Brazil.

Authors:  Ana Luiza Bierrenbach; Ruth Minamisava; Airlane Pereira Alencar; Gizelton Pereira Alencar; Ana Lucia Andrade
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

6.  Invasive pneumococcal disease in hospitalised children from Lima, Peru before and after introduction of the 7-valent conjugated vaccine.

Authors:  A Luna-Muschi; F Castillo-Tokumori; M P Deza; E H Mercado; M Egoavil; K Sedano; M E Castillo; I Reyes; E Chaparro; R Hernández; W Silva; O Del Aguila; F Campos; A Saenz; T J Ochoa
Journal:  Epidemiol Infect       Date:  2019-01       Impact factor: 2.451

7.  Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study.

Authors:  Laura L Hammitt; Anthony O Etyang; Susan C Morpeth; John Ojal; Alex Mutuku; Neema Mturi; Jennifer C Moisi; Ifedayo M Adetifa; Angela Karani; Donald O Akech; Mark Otiende; Tahreni Bwanaali; Jackline Wafula; Christine Mataza; Edward Mumbo; Collins Tabu; Maria Deloria Knoll; Evasius Bauni; Kevin Marsh; Thomas N Williams; Tatu Kamau; Shahnaaz K Sharif; Orin S Levine; J Anthony G Scott
Journal:  Lancet       Date:  2019-04-15       Impact factor: 79.321

Review 8.  Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review.

Authors:  Lucia Helena de Oliveira; Luiz Antonio B Camacho; Evandro S F Coutinho; Martha S Martinez-Silveira; Ana Flavia Carvalho; Cuauhtemoc Ruiz-Matus; Cristiana M Toscano
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

9.  A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand.

Authors:  Lijoy Varghese; Louise Talbot; Andrea Govender; Xu-Hao Zhang; Bruce A Mungall
Journal:  Appl Health Econ Health Policy       Date:  2018-06       Impact factor: 2.561

10.  Impact of 10-Valent Pneumococcal Conjugate Vaccine on Bacterial Meningitis in Madagascar.

Authors:  Emilson Jean P R Andriatahirintsoa; Julia Liliane Raboba; Vonintsoa Lalaina Rahajamanana; Ando Lalaina Rakotozanany; Mengouom M Nimpa; Yolande Vuo Masembe; Goitom Weldegebriel; Linda De Gouveia; Jason M Mwenda; Annick Lalaina Robinson
Journal:  Clin Infect Dis       Date:  2019-09-05       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.